Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces erlotinib-induced subacute toxicity in rat

Journal of Biomedical Nanotechnology

Volumn 5, Issue 5, 2009, Pages 464-471

  Marslin, Gregory ^a,c   Sheeba, Caroline J ^b   Kalaichelvan, V K ^a   Manavalan, R ^a   Reddy, P Neelakanta ^c   Franklin, G ^d  

^a ANNAMALAI UNIVERSITY   (India)

^b UNIVERSITY OF MINHO   (Portugal)

^c CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

Erlotinib HCI; Non small cell lung cancer; PLGA nanoparticle; Subacute toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENCAPSULATED NANOPARTICLES; ERLOTINIB; HAEMOGLOBINS; INTERNAL ORGANS; NANO PARTICULATES; NANO-ENCAPSULATION; NON SMALL CELL LUNG CANCER; PLGA NANOPARTICLE; PLGA NANOPARTICLES; POLY(D , L-LACTIC-CO-GLYCOLIC ACID); QUINAZOLINES; RED BLOOD CELL; TOXIC EFFECT; WHITE BLOOD CELLS; WISTAR RAT;

ACIDS; ANIMALS; BIOLOGICAL ORGANS; BLOOD; CELLS; ELECTRIC CURRENTS; NANOPARTICLES; PLANTS (BOTANY); RATS; TOXICITY;

DRUG THERAPY;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ERLOTINIB; HEMOGLOBIN; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; ERYTHROCYTE; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; LEUKOCYTE; MALE; NANOENCAPSULATION; NEUTROPHIL COUNT; NONHUMAN; RAT; TOXICITY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG TOXICITY; LACTIC ACID; MATERIALS TESTING; NANOCAPSULES; NANOMEDICINE; POLYGLYCOLIC ACID; QUINAZOLINES; RATS; RATS, WISTAR;

EID: 76749143007     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1075     Document Type: Article

References (34)

1. S. S. Sridhar, L. Seymour, and F. A. Shepherd, Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on nonsmall-cell lung cancer. Lancet Oncol. 4, 397 (2003).
2. Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2, 127 (2001).
3. A. Sandler and R. Herbst, Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res. 12, 4421 (2006).
4. R. Pérez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, and M. Huberman, Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238 (2004).
5. D. K. Sahana, G. Mittal, V. Bhardwaj, and M. N. V. Ravikumar, PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behaviour in vitro and in vivo using estradiol as a model drug. J. Pharm. Sci. 97, 1530 (2008).
6. K. S. Kumar, V. Selvaraj, and M. Alagar, Synthesis of PETPLA/Drug nanoparticles and their effect with gold nanoparticles for controlled drug release in cancer chemotherapy. Res. Lett. Nanotechnol. 2008, 4 (2008).
7. S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer, and W. C. Chan, Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909 (2009).
8. G. S. Kwon and T. Okano, Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev. 16, 107 (1996).
9. H. S. Yoo, J. E. Oh, K. H. Lee, and T. G. Park, Biodegradable nanoparticles containing doxorubicin-PLGA conjugates for sustained release. Pharm. Res. 16, 1114 (1999).
10. E. Allemann, R. Gurny, and J. C. Leroux, Boidegradable nanoparticles of poly(lactic-co-glycolic acid) for parenteral administration, Pharmaceutical Dosage Forms: Disperse Systems, edited by H. A. Liberman, M. M. Reiger, and G. S. Banker, Marcel Dekker, New York (1996), pp. 163-194.
11. K. S. Soppimath and T. M. Aminabhavi, Ethyl acetate as a dispersing solvent in the production of poly(D,L-lactideco-glycolide) microspheres: Effect of process parameters and polymer type. J. Microencapsulat. 19, 281 (2002).
12. M. M. Arnold, E. M. Gorman, L. J. Schieber, E. J. Munson, and C. Berland, NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release 16, 100 (2007).
13. R. A. Jain, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475 (2000).
14. I. Bala, S. Hariharan, and M. N. V. R. Kumar, PLGA nanoparticles in drug delivery: The state of the art. Crit. Rev. Ther. Drug Carrier Syst. 21, 387 (2004).
15. R. Lin, L. Shi Nq, and C. H. Wang, In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials 26, 4476 (2005).
16. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, and R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 103, 6315 (2006).
17. A. Budhian, S. J. Siegel, and K. I. Winey, Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int. J. Pharm. 336, 367 (2007).
18. S. K. Jain, Y. Gupta, A. Jain, A. R. Saxena, P. Khare, and A. Jain, Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery. Nanomedicine 4, 41 (2008).
19. F. Danhier, N. Lecouturier, B. Vroman, C. Jérôme, J. Marchand-Brynaert, O. Feron, and V. Préat, Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J. Control. Release 133, 11 (2009).
20. K. Park, G. Y. Lee, Y. S. Kim, M. Yu, R. W. Park, I. S. Kim, S. Y. Kim, and Y. Byun, Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J. Control. Release 114, 300 (2006).
21. V. Bhardwaj, S. Hariharan, I. Bala, A. Lamprecht, N. Kumar, R. Panchagnula, and M. N. V. Ravi Kumar, Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J. Biomed. Nanotechnol. 1, 235 (2005).
22. A. T. Florence, Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discovery Today Technol. 2, 75 (2005).
23. J. T. Hartmann, M. Haap, H. G. Kopp, and H. P. Lipp, Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10, 470 (2009).
24. EMEA, 2005. http://www.emea.europa.eu/humandocs/PDFs/EPAR/tarceva/ 061805en6.pdf (accessed on 16 Aug 2009).
25. A. O. Amakiri, O. J. Owen, E. M. Ngodigha, and D. O. Jack, Effect of refined petroleum product (kerosene) flame and fumes on serum enzyme characteristics of broiler chickens. Int. J. Poult. Sci. 7, 1039 (2008).
26. S. K. Murthy, Nanoparticles in modern medicine: State of the art and future challenges. Int. J. Nanomedicine 2, 129 (2007).
27. C. Fonseca, S. Simoes, and R. Gaspar, Paclitaxel-loaded PLGA nanoparticles: Preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83, 273 (2002).
28. J. M. Koziara, T. R. Whisman, M. T. Tseng, and R. J. Mumper, In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 112, 312 (2006).
29. H. S. Yoo, K. H. Lee, J. E. Oh, and T. G. Park, In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Release 68, 419 (2000).
30. D. Bhadra, S. Bhadra, S. Jain, and N. K. Jain, A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257, 111 (2003).
31. J. Panyam and V. Labhasetwar, Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharm. 1, 77 (2004).
32. J. L. Italia, D. K. Bhatt, V. Bhardwaj, K. Tikoo, and M. N. V. Ravi Kumar, PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Control. Release 119, 197 (2007).
33. D. R. Kalaria, G. Sharma, V. Beniwal, and M. N. V. Ravi Kumar, Design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharmaceutical Res. 26, 492 (2008).
34. G. Mittal, D. K. Sahana, V. Bhardwaj, and M. N. V. Ravi Kumar, Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Release 119, 77 (2007).